Full-Time
Credentialing and Enrollment Coordinator
Multiple Teams
Posted on 10/1/2025
ArteraAI
51-200 employees
Delivers CLIA-certified multi-modal prostate cancer test
Compensation Overview
$28 - $33/hr
Remote in USA
Remote
 Legal & Compliance (1) |
|---|
- Associates degree required.
- 2 or more years of experience in credentialing and payer enrollment, preferably in a clinical laboratory.
- Strong knowledge of Type 2 NPI credentialing and enrollment processes with Medicare, Medicaid, and commercial payers.
- Hands-on experience with EDI, ERA, and EFT enrollment and troubleshooting.
- Familiarity with payer portals, PECOS, and clearinghouse platforms.
- Excellent organizational skills with the ability to manage multiple projects and deadlines.
- Strong written and verbal communication skills.
- Coordinate credentialing and re-credentialing activities for the laboratory.
- Prepare and submit payer applications, contracts, and supporting documents.
- Track enrollment status with Medicare, Medicaid, and commercial payers.
- Maintain accurate records of credentialing and enrollment activities.
- Initiate and manage EDI, ERA, and EFT enrollment requests with payers.
- Coordinate with clearinghouse and payers to troubleshoot transmission issues.
- Ensure all electronic connections are tested and verified for claims and remittances.
- Ensure compliance with payer-specific requirements and regulations.
- Maintain up-to-date provider files and documentation for audits and reporting.
- Monitor credentialing and enrollment deadlines to prevent lapses in participation.
- Serve as a point of contact for payers, providers, and internal teams regarding credentialing and enrollment status.
ArteraAI develops personalized prostate cancer therapy solutions using multi-modal deep learning. Its flagship offering, the ArteraAI Prostate Test, is a high-complexity CLIA-certified clinical laboratory test performed in-house and used in clinical care. The test analyzes diverse data through advanced AI to tailor treatment decisions for individual patients. Unlike many competitors, ArteraAI integrates randomized phase III trial-informed science, in-house product development, and routine publications to support credibility, and targets a shift toward personalized, data-driven prostate cancer therapies. The company's goal is to equip healthcare providers with reliable, data-backed tools to personalize treatment plans, improving outcomes for patients while expanding adoption across hospitals, clinics, and other care settings.
Company Size
51-200
Company Stage
Early VC
Total Funding
$175M
Headquarters
Menlo Park, California
Founded
2021
Simplify's Take
What believers are saying
- Tempus partnership accesses 50% of US oncologists, driving ArteraAI Prostate test adoption.
- FDA clearance for ArteraAI Breast in 2026 validates MMAI platform expansion beyond prostate.
- $65M investment and $100M CARR milestone signal strong commercial traction.
What critics are saying
- Tempus exclusivity enables pricing pressure and volume diversion to its AI tools within 12 months.
- Paige.AI's FDA-cleared prostate AI steals pathology lab contracts from Artera in 6 months.
- Decipher and Oncotype DX dominate NCCN guidelines, undercutting Artera reimbursement in 12 months.
What makes ArteraAI unique
- ArteraAI Prostate Test uniquely predicts hormone therapy benefit and prognosticates outcomes using MMAI on biopsy images.
- First AI test included in 2024 NCCN Guidelines with Level IB evidence from Phase 3 trials.
- FDA Breakthrough Designation for ArteraAI Prostate on July 9, 2025, accelerates approval.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↑ 0%Daniel Spratt, MD, on using ArteraAI to guide salvage therapy decisions. Daniel Spratt, MD, discusses how the ArteraAI Prostate Test (Post-RP) could help guide treatment intensification decisions. On December 9, 2025, Artera announced the commercial launch of the ArteraAI Prostate Test (Post-RP), a tool designed to help identify which patients with biochemical recurrence following radical prostatectomy may benefit from intensified salvage therapy.[1] Specifically, the multimodal artificial intelligence (MMAI) test provides prognostic insight into the potential benefit of adding short-term androgen deprivation therapy (ADT) to radiation. In an interview with Urology Times(R), Daniel Spratt, MD, a radiation oncologist at University Hospitals Seidman Cancer Center in Cleveland, Ohio, discussed the clinical challenges of managing biochemical recurrence and how the ArteraAI Prostate Test (Post-RP) could help guide treatment intensification decisions. According to Spratt, clinicians have long lacked a reliable tool to support decision-making in this setting - a gap the ArteraAI Prostate Test was developed to address. Spratt explained, "This [test] uses [patients'] clinical and pathologic features as well as, very importantly, digital pathology, running an artificial intelligence algorithm to help us put all these features together to identify patients at low risk of developing recurrence and metastatic disease vs those patients at much higher risk." "When you use this MMAI test, it's really profound. Those with a low MMAI score have a much lower risk of developing recurrence or metastatic disease. So, the benefit of hormone therapy is only a couple percent. It's not zero, but it's a much smaller benefit vs when you find a patient who has a high MMAI score, [where] you're talking about benefits of 20% or higher in terms of reductions in metastatic disease," said Spratt. 1. Artera debuts ArteraAI Prostate Test (Post-RP), expanding its oncology portfolio. News release. Artera. December 9, 2025. Accessed January 1, 2025. 2. New data validating the first AI-based biomarker to stratify risk of metastasis in radical prostatectomy patients with biochemical recurrence. News release. Artera. May 6, 2024. Accessed January 1, 2025. Stay current with the latest urology news and practice-changing insights - sign up now for the essential updates every urologist needs.
Artera announces a $65M growth investment and a major milestone of reaching $100 million in Contracted Annual Recurring Revenue (CARR)..
Sept. 26, 2025 - Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present four abstracts at the 2025 American Society for Radiation Oncology Annual Meeting (ASTRO) in San Francisco, Calif..
Artera presenting validation data at 2025 ASCO Annual Meeting highlighting how multimodal AI platform (MMAI) is advancing personalized cancer care.
AI Study Challenges Fears of Racial Bias in Prostate Cancer Care. by Fred Pennic 05/09/2025 Leave a Comment. What You Should Know: – Artera, a company developing multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the publication of a significant validation study in the JCO Clinical Cancer Informatics. – The study rigorously assessed Artera’s MMAI model and confirmed its ability to perform similarly across different racial subgroups using data from diverse prostate cancer clinical trials.Addressing the Challenge of AI Racial Bias in OncologyThis research comes at a crucial time as AI tools are increasingly integrated into clinical decision-making. However, valid concerns persist that these technologies could inadvertently worsen healthcare inequities due to racial bias, particularly if developed using datasets not representative of real-world patient populations. This is a pronounced concern in prostate cancer, where African American men have historically faced a worse prognosis, partly attributed to their underrepresentation in the development of AI tools and genomic biomarkers. Many current AI models have been trained on datasets that lack diversity, raising questions about their applicability and fairness across all patient groups